Biointron

Founded in 2012 and certified to ISO 9001:2015, Biointron is a CRO specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies.

The Latest Insights & Innovations from

Biointron

AI-Ready, Lab-Proven: A New Standard for High-Throughput Antibody Characterization

July 30, 2026

Accelerating Antibody Discovery: Integrating Microfluidics, HT Expression, and Early Developability Platform

April 30, 2026

From Single Domain to Single B: Leveraging Biointron's Expertise for Antibody Discovery Success

October 16, 2025

Introduction to Bispecific Antibodies and Their Production

May 15, 2025

Accelerating the Design–Build–Test–Learn Cycle for AI-Driven Antibody Discovery

June 25, 2026

The Case for Early Developability Assessment in Antibody Discovery

December 9, 2025

From Target to Therapeutic: Rethinking Antibody Discovery

September 25, 2025

The Role of Recombinant Antibody Platforms in Advancing Therapeutic Development: Key Insights and Considerations for Production Success

August 21, 2025

No items found.